SMT202000576T1 - Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi - Google Patents

Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi

Info

Publication number
SMT202000576T1
SMT202000576T1 SM20200576T SMT202000576T SMT202000576T1 SM T202000576 T1 SMT202000576 T1 SM T202000576T1 SM 20200576 T SM20200576 T SM 20200576T SM T202000576 T SMT202000576 T SM T202000576T SM T202000576 T1 SMT202000576 T1 SM T202000576T1
Authority
SM
San Marino
Prior art keywords
neurological
disorders
treatment
neurodegenerative diseases
intranasal compositions
Prior art date
Application number
SM20200576T
Other languages
English (en)
Italian (it)
Inventor
Timothy Matthias Morgan
Original Assignee
Lachesis Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903944A external-priority patent/AU2014903944A0/en
Application filed by Lachesis Biosciences Ltd filed Critical Lachesis Biosciences Ltd
Publication of SMT202000576T1 publication Critical patent/SMT202000576T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20200576T 2014-10-03 2015-09-30 Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi SMT202000576T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903944A AU2014903944A0 (en) 2014-10-03 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
EP15848100.2A EP3200828B1 (en) 2014-10-03 2015-09-30 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
PCT/AU2015/050591 WO2016049700A1 (en) 2014-10-03 2015-09-30 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Publications (1)

Publication Number Publication Date
SMT202000576T1 true SMT202000576T1 (it) 2020-11-10

Family

ID=55629161

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200576T SMT202000576T1 (it) 2014-10-03 2015-09-30 Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi

Country Status (12)

Country Link
US (3) US10471040B2 (enExample)
EP (1) EP3200828B1 (enExample)
JP (3) JP2017530195A (enExample)
AU (1) AU2015327762C1 (enExample)
CA (1) CA2961936C (enExample)
DK (1) DK3200828T3 (enExample)
ES (1) ES2822562T3 (enExample)
HU (1) HUE052441T2 (enExample)
PL (1) PL3200828T3 (enExample)
PT (1) PT3200828T (enExample)
SM (1) SMT202000576T1 (enExample)
WO (1) WO2016049700A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3200828T3 (pl) * 2014-10-03 2021-01-25 Lachesis Biosciences Limited Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych
SI3698791T1 (sl) * 2017-02-02 2024-05-31 Otolanum Ag Intranazalni sestavek, ki vsebuje betahistin
US20230172895A1 (en) * 2020-06-25 2023-06-08 Lachesis Biosciences Limited Methods of treating or preventing organophosphorus poisoning
CN116322647A (zh) * 2020-08-07 2023-06-23 科学和工业研究委员会 用于治疗急性呼吸窘迫综合征的微乳剂药物递送体系
GB2614167A (en) * 2020-10-01 2023-06-28 Lyra Therapeutics Inc Osmotic drug delivery implants
CN115919767B (zh) * 2022-10-13 2023-08-11 暨南大学 卡巴拉汀鼻喷雾剂及其制备方法
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (enExample) 1966-09-27 1968-01-22
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
FR2722989B1 (fr) 1994-07-29 1997-05-30 Synthelabo Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales
US6558560B2 (en) * 2001-07-27 2003-05-06 Hewlett-Packard Company Method for the fabrication of electrical contacts
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
EP1811979B1 (en) * 2004-09-27 2008-11-05 Sigmoid Pharma Limited Microcapsules comprising a methylxanthine and a corticosteroid
US8187570B1 (en) * 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2007043057A2 (en) * 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CA2641392A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
EP1981475A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
KR20100031608A (ko) * 2007-06-26 2010-03-23 와카모토 세이야꾸 가부시끼가이샤 수성 조성물
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
MY165234A (en) 2010-05-17 2018-03-14 Forum Pharmaceuticals Inc A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US8673338B2 (en) * 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
PL3200828T3 (pl) * 2014-10-03 2021-01-25 Lachesis Biosciences Limited Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych

Also Published As

Publication number Publication date
JP2022003100A (ja) 2022-01-11
ES2822562T3 (es) 2021-05-04
EP3200828A4 (en) 2018-04-25
JP2020090547A (ja) 2020-06-11
US11911360B2 (en) 2024-02-27
DK3200828T3 (da) 2020-10-12
US20210145789A1 (en) 2021-05-20
AU2015327762C1 (en) 2020-10-22
EP3200828B1 (en) 2020-08-12
US10933045B2 (en) 2021-03-02
US20170239209A1 (en) 2017-08-24
JP2017530195A (ja) 2017-10-12
PL3200828T3 (pl) 2021-01-25
HUE052441T2 (hu) 2021-04-28
US20200078331A1 (en) 2020-03-12
PT3200828T (pt) 2020-10-08
AU2015327762A1 (en) 2017-04-20
US10471040B2 (en) 2019-11-12
WO2016049700A1 (en) 2016-04-07
JP7357571B2 (ja) 2023-10-06
AU2015327762B2 (en) 2020-06-25
CA2961936A1 (en) 2016-04-07
EP3200828A1 (en) 2017-08-09
CA2961936C (en) 2023-03-14

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL248732B (en) Compounds for the treatment of ophthalmological diseases and disorders
IL269106A (en) Methods for the treatment of neurodegenerative diseases
ZA201903003B (en) Treatment of neurological diseases
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
PT3200828T (pt) Composições intranasais para o tratamento de doenças e distúrbios neurológicos e neurodegenerativos
IL320533A (en) Methods and compositions for treating disorders and diseases involving RDH12
GB201516905D0 (en) Treatment of Neurodegenerative diseases
GB201412578D0 (en) Treatment of neurological diseases
GB201408387D0 (en) Treatment of respiratory disorders
GB201612043D0 (en) Composition for treatment of disorders
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
LT3458067T (lt) Neurologinių sutrikimų gydymas
GB201714307D0 (en) Treatment of neurodegenerative diseases
PL3377089T3 (pl) Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201714303D0 (en) Treatment of neurodegenerative diseases
SG11201706952VA (en) Compositions and methods for the treatment of epilepsy and neurological disorders
AU2014903944A0 (en) Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
GB201704666D0 (en) Treatment of neurodegenerative diseases
GB201602784D0 (en) New treatment of CFTR-related disorders
IL254140A0 (en) Preparations and combinations for use in the treatment of angiogenic diseases and disorders